190815 Chequeoverhandiging Team Edith

Donation for a new form of immunotherapy

Thanks to your generous donations to the Antoni van Leeuwenhoek Foundation, John Haanen was able to start his research into TIL treatment, a new form of immunotherapy that works by activating the body’s own immune response against cancer.

The TIL study (phase III trial) researches TIL therapy as a treatment option for patients with metastatic melanoma. This experimental treatment using the body’s own immune cells, the Tumor Infiltrating Lymphocytes (TILs), is often compared to a similar type of immunotherapy that has been available in the Netherlands since 2011: ipilimumab, a medicine that targets a protein that downregulates the immune response to the tumor, which shows a temporary or even long-term effect on the cancer in 10 to 20% of patients.

Steps TIL treatment
TIL immunotherapy treatment consists of several steps: First, a surgeon will remove a small piece of the tumor. The cancer cells found in this tissue sample will be isolated, altered, and grown into millions of T-cells over the course of five weeks. Meanwhile, the patients will receive chemotherapy treatment during their hospital stay to prepare the bloodstream for the millions of TIL-cells that will be returned to the body. The patient will then be hooked up to an IV for the infusion of the TIL-cells together with interleukin-2, a protein that will help the TIL-cells stay activated to destroy cancer cells. After a hospital stay of seven days, the patient can go home and will return for a follow-up consultation later.

Promising developments
John Haanen is optimistic about his research: “About 500 patients with metastatic melanomas received TIL, and approximately half of them have noticeably improved: we see a 30 to 40% decrease in the metastases. The treatment is clearly beneficial, even though it doesn’t always cure the illness: about 10% of patients are recovered after the treatment. The chance of recurrence is very small. All this considered, TIL treatment seems to be a promising development for people with melanomas, and perhaps, eventually, even for people with other types of cancer.”

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.